ATRA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 107373 min ago

@ $0.771

Išleistas: 14 vas. 2024 @ 20:55

Grąža: -10.52%

Ankstesnis signalas: vas. 13 - 22:34

Ankstesnis signalas: Pardavimas

Grąža: -0.05 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States...

Stats
Šios dienos apimtis	519 733
Vidutinė apimtis	2.67M
Rinkos kapitalizacija	82.36M
EPS	$0 ( 2024-03-27 )
Kita pelno data	( $-0.370 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.260
ATR14	$0.00200 (0.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Fust Matthew K	Buy	150 000	Common Stock
2024-03-31	Heiden William K	Buy	150 000	Common Stock
2024-03-31	Roncarolo Maria Grazia	Buy	150 000	Common Stock
2024-03-31	Gallagher Carol Giltner	Buy	150 000	Common Stock
2024-03-31	Mallik Ameet	Buy	150 000	Common Stock

INSIDER POWER
70.32
Last 100 transactions
Buy: 8 350 944 \| Sell: 2 074 393

Tūris Koreliacija

Ilgas: -0.13 (neutral)

Trumpas: 0.82 (strong)

Signal:(52.538) Same movement expected

Atara Biotherapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SRTS	0.965
CDXS	0.964
LGHL	0.959
ZD	0.957
ZYNE	0.952
RKDA	0.95
ATER	0.949
HNNA	0.948
NMTR	0.948
DYNT	0.946

10 Labiausiai neigiamai susiję koreliacijos
MCAA	-0.951
MSDA	-0.949
CITE	-0.945
DHAC	-0.944
AHRN	-0.942
LEGA	-0.942
ADAL	-0.942
FTAA	-0.94
PFTA	-0.939
ZING	-0.939

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Atara Biotherapeutics Inc Koreliacija - Valiuta/Žaliavos

-0.60
( weak negative )

-0.57
( weak negative )

0.00
( neutral )

0.85
( strong )

Atara Biotherapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$8.57M
Bruto pelnas:	$-313 000 (-3.65 %)
EPS:	$-2.61

FY	2023
Pajamos:	$8.57M
Bruto pelnas:	$-313 000 (-3.65 %)
EPS:	$-2.61

FY	2022
Pajamos:	$63.57M
Bruto pelnas:	$49.01M (77.08 %)
EPS:	$-2.24

FY	2021
Pajamos:	$20.34M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-3.63

Financial Reports:

No articles found.

Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.